Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Annexon Biosciences
< Previous
1
2
Next >
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
October 21, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
October 15, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
September 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
September 09, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
September 03, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Participate in Upcoming September Investor Conferences
August 29, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
August 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
August 12, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
August 05, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
July 11, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
June 25, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
June 18, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Announces Pricing of $125 Million Underwritten Public Offering
June 05, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Announces Proposed Public Offering of Common Stock
June 04, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
June 04, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
June 03, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
May 13, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Present at the Bank of America Health Care Conference
May 09, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
May 07, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
May 01, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
March 26, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 18, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
February 21, 2024
From
Annexon Biosciences
Via
GlobeNewswire
Tickers
ANNX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.